Magenta Therapeutics, Inc. announced that it has received a clinical hold letter from the US FDA related to its Investigational New Drug Application filed in June 2021 to initiate a Phase I/II clinical trial of MGTA-117 in patients with acute myeloid leukemia and myelodysplastic syndrome.
[Magenta Therapeutics, Inc.]
7992332
{7992332:nan}
apa
50
1
164981
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/